Pooled analysis of fluorouracil-based adjuvant therapy for stage II and III colon cancer: who benefits and by how much?
Sharlene Gill , Charles L. Loprinzi , Daniel J. Sargent , Stephan D. Thomé
Journal of Clinical Oncology 22 ( 10) 1797 -1806
1,263
2004
A Randomized Controlled Trial of Fluorouracil Plus Leucovorin, Irinotecan, and Oxaliplatin Combinations in Patients With Previously Untreated Metastatic Colorectal Cancer
Richard M. Goldberg , Daniel J. Sargent , Roscoe F. Morton , Charles S. Fuchs
Journal of Clinical Oncology 22 ( 1) 23 -30
2,883
2004
Intraepithelial Effector (CD3+)/Regulatory (FoxP3+) T-Cell Ratio Predicts a Clinical Outcome of Human Colon Carcinoma
Frank A. Sinicrope , Rafaela L. Rego , Stephen M. Ansell , Keith L. Knutson
Gastroenterology 137 ( 4) 1270 -1279
219
2009
Mortality associated with daily bolus 5-fluorouracil/leucovorin administered in combination with either irinotecan or oxaliplatin: results from Intergroup Trial N9741.
Thierry Delaunoit , Richard M. Goldberg , Daniel J. Sargent , Roscoe F. Morton
Cancer 101 ( 10) 2170 -2176
64
2004
A pilot study of high-dose intraarterial cisplatin chemotherapy with concomitant accelerated radiotherapy for patients with previously untreated T4 and selected patients with T3N0-N3M0 squamous cell carcinoma of the upper aerodigestive tract.
Robert L. Foote , Jan L. Kasperbauer , Scott H. Okuno , Douglas A. Nichols
Cancer 103 ( 3) 559 -568
26
2005
Clinical Trials of Novel and Targeted Therapies: Endpoints, Trial Design, and Analysis
Vera J. Suman , Amylou Dueck , Daniel J. Sargent
Cancer Investigation 26 ( 5) 439 -444
15
2008
A Flexible Approach to Time-varying Coefficients in the Cox Regression Setting
Daniel J. Sargent
Lifetime Data Analysis 3 ( 1) 13 -25
72
1997
Stool DNA and Occult Blood Testing for Screen Detection of Colorectal Neoplasia
David A. Ahlquist , Daniel J. Sargent , Charles L. Loprinzi , Theodore R. Levin
Annals of Internal Medicine 149 ( 7) 441 -450
249
2008
Adjuvant Therapy for Colon Cancer: Small Steps Toward Precision Medicine
Axel Grothey , Daniel J. Sargent
JAMA Oncology 2 ( 9) 1133 -1134
5
2016
Use of Bayesian Decision Analysis to Minimize Harm in Patient-Centered Randomized Clinical Trials in Oncology.
Vahid Montazerhodjat , Shomesh E. Chaudhuri , Daniel J. Sargent , Andrew W. Lo
JAMA Oncology 3 ( 9)
13
2017
Association of DNA Mismatch Repair and Mutations in BRAF and KRAS With Survival After Recurrence in Stage III Colon Cancers : A Secondary Analysis of 2 Randomized Clinical Trials.
Frank A. Sinicrope , Qian Shi , Carmen J. Allegra , Thomas C. Smyrk
JAMA Oncology 3 ( 4) 472 -480
46
2017
Structured Markov Chain Monte Carlo
Daniel J. Sargent , James S. Hodges , Bradley P. Carlin
Journal of Computational and Graphical Statistics 9 ( 2) 217 -234
43
2000
Clinical trial designs incorporating predictive biomarkers.
Lindsay A. Renfro , Himel Mallick , Ming-Wen An , Daniel J. Sargent
Cancer Treatment Reviews 43 74 -82
37
2016
Bayesian Variable Selection with Joint Modeling of Categorical and Survival Outcomes: An Application to Individualizing Chemotherapy Treatment in Advanced Colorectal Cancer
Wei Chen , Debashis Ghosh , Trivellore E. Raghunathan , Daniel J. Sargent
Biometrics 65 ( 4) 1030 -1040
14
2009
Hierarchical Commensurate and Power Prior Models for Adaptive Incorporation of Historical Information in Clinical Trials
Brian P. Hobbs , Bradley P. Carlin , Sumithra J. Mandrekar , Daniel J. Sargent
Biometrics 67 ( 3) 1047 -1056
148
2011
Meta-analysis for Surrogacy: Accelerated Failure Time Models and Semicompeting Risks Modeling
Debashis Ghosh , Jeremy M. G. Taylor , Daniel J. Sargent
Biometrics 68 ( 1) 226 -232
14
2012
Bayesian Adaptive Trial Design for a Newly Validated Surrogate Endpoint
Lindsay A. Renfro , Bradley P. Carlin , Daniel J. Sargent
Biometrics 68 ( 1) 258 -267
7
2012
Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time.
Stuart G. Baker , Daniel J. Sargent , Marc Buyse , Tomasz Burzykowski
Biometrics 68 ( 1) 248 -257
14
2012
Isolated Loss of PMS2 Expression in Colorectal Cancers: Frequency, Patient Age, and Familial Aggregation
Sharlene Gill , Noralane M. Lindor , Lawrence J. Burgart , Regenia Smalley
Clinical Cancer Research 11 ( 18) 6466 -6471
50
2005
Thymidylate Synthase Expression in Colon Carcinomas with Microsatellite Instability
Frank A. Sinicrope , Rafaela L. Rego , Kevin C. Halling , Nathan R. Foster
Clinical Cancer Research 12 ( 9) 2738 -2744
41
2006